Extended Data Fig. 7: App AKO protects mice from obesity with enhanced adipocyte mitochondrial function (related to Fig. 6e–h).
a,b, Experiments were in 12-week HFD/Dox feeding control or App AKO mice. a, Insulin levels measured in serum samples obtained from OGTT experiments. b, Glucose levels at difference time points during ITT assays. n = 8 mice per group. c–g, For insulin-sensitivity measurement, three groups of mice, including control, APP adipocyte-specific transgenic (App Tg) and App adipocyte-specific knockout (App AKO) mice were subjected to hyperinsulinemic–euglycemic clamp studies. c, Body weight. d, Clamped glucose levels. e, GIR. f, Basal hepatic glucose production. g, 2-DG uptake in different metabolic tissues. For c–f, n = 7 mice in control and App Tg groups, n = 6 mice in App AKO group. For g, n = 6 mice per group. h,i, Representative immunoblot image of p-Akt (Ser 473) and total Akt expression in different metabolic tissues from both control and APP-overexpressing mice (h) or both control and App AKO mice (i) after saline or insulin injection (i.v.) for 5 min. For the western blot image, n = 3 mice per group, and the representative images are chosen from three independent experiments. Dare shown as mean ± s.e.m. of biologically independent samples. Two-way ANOVA followed by a Tukey post-test (a,b); one-way ANOVA followed by a Tukey post-test (c–g).
